Inhibition of 8-OH-DPAT-induced elevation of plasma corticotrophin by the 5-HT1A receptor antagonist WAY100635

Critchley, David; Childs, Kirstie; Middlefell, Vicki C.; Dourish, C T

doi:10.1016/0014-2999(94)90642-4

Cited by 35 publications

(14 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously tested the specificity of the effect of 8-OH-DPAT by examining its ability to release hormones in the presence of antagonists. An increase in plasma levels of oxytocin and ACTH induced by 8-OH-DPAT is blocked by the 5-HT 1A receptor antagonists WAY100635, NAN190, and pindolol (Bagdy and Kalogeras, 1993;Critchley et al, 1994;Meller and Bohmaker, 1994;Vicentic et al, 1998). Thus, an alteration in plasma levels of oxytocin and ACTH after an injection with (ϩ)8-OH-DPAT is not mediated by activation DOI is the most selective 5-HT 2A/2C receptor agonist available to date, with similar affinities for 5-HT 2A and 5-HT 2C receptors (Hoyer, 1988;Van Wijngaarden et al, 1990).…”

Section: Discussionmentioning

confidence: 99%

Desensitization of 5-HT_1AReceptors by 5-HT_2AReceptors in Neuroendocrine Neurons in Vivo

Zhang¹,

Gray²,

D’Souza³

et al. 2004

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Desensitization of 5-HT_1AReceptors by 5-HT_2AReceptors in Neuroendocrine Neurons in Vivo

Zhang¹,

Gray²,

D’Souza³

et al. 2004

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

“…To this end, rats were co-treated in turn with the non selective 5-HT receptor antagonist metergoline, the effects. In rats, metergoline can influence components of behaviour including a suppression of rearing, sniffing and locomotion at doses of 2mg/kg and higher (Halford and Blundell, 1996;Mockler et al, 1983;Wilson et al, 1998) or lower are required to block both the pre and postsynaptic effects of 8-OH DPAT (Critchley et al, 1994;Forster et al, 1995;Moser and Sanger, 1999). Both agents have previously been reported to lack activity in the FST (De Vry et al, 2004;Tatarczyńska et al, 2004) …”

Section: Accepted M Manuscriptmentioning

confidence: 99%

A role for serotonin in the antidepressant activity of NG-Nitro-L-arginine, in the rat forced swimming test

Gigliucci

Buckley

Nunan

et al. 2010

Pharmacology Biochemistry and Behavior

View full text Add to dashboard Cite

show abstract

“…From these studies, investigators have begun to characterize the underlying mechanisms of neuroendocrine responses to 5-HT1A receptor agonist challenge. In the naive rat, systemic injection of the selective serotonin 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), elicits dose-dependent increases in plasma levels of ACTH and oxytocin as well as robust increases in corticosterone, all of which are blocked by systemic administration of the selective 5-HT1A receptor antagonist, WAY100635 (Bagdy and Kalogeras, 1993;Critchley et al, 1994;Bagdy, 1996;Vicentic et al, 1998).…”

mentioning

confidence: 99%

5-Hydroxytryptamine 1A Receptors in the Paraventricular Nucleus of the Hypothalamus Mediate Oxytocin and Adrenocorticotropin Hormone Release and Some Behavioral Components of the Serotonin Syndrome

Osei‐Owusu

James²,

Crane³

et al. 2005

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Neuroendocrine responses to administration of serotonin releasing agents or 5-hydroxytryptamine (5-HT) 1A receptor agonists have been used as an index of serotonin receptor function in patients with depression and other mood disorders. However, the receptor population that mediates these responses has not been clearly identified. We tested the hypothesis that 5-HT1A receptors in the paraventricular nucleus of the hypothalamus (PVN) mediate the release of adrenocorticotropin hormone (ACTH) and oxytocin after administration of a selective 5-HT1A agonist in conscious rats. Low-dose infusion (1 nmol/ 100 nl/side) of the selective 5-HT1A antagonist, WAY100635 (WAY; [O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl) ethyl)-N-(2-pyridinyl)cyclohexanecarboxamidetrihydrochloride), into the PVN blocked the rise in ACTH and oxytocin stimulated by low-dose (30 nmol/kg) i.v. administration of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 274 Ϯ 53 versus 70 Ϯ 20 pg/ml, P Ͻ 0.01 for ACTH and 10.7 Ϯ 3.4 versus 4.6 Ϯ 0.7 pg/ml, P Ͻ 0.05 for oxytocin after saline or WAY pretreatment, respectively). WAY did not influence the bradycardic effect of 8-OH-DPAT (Ϫ56 Ϯ 7 versus Ϫ54 Ϯ 6 beats per minute after saline or WAY). 8-OH-DPAT treatment also elicited locomotor activation followed by hind limb abduction and flat body posture. Surprisingly, WAY attenuated some aspects of locomotor activation and reduced the duration of hind limb abduction elicited by the agonist (5.1 Ϯ 0.9 versus 0.3 Ϯ 0.3 min for saline-or WAY-treated rats). These data indicate that 5-HT1A receptor stimulation in the PVN mediates the characteristic neuroendocrine response to serotonin agonist challenge. Moreover, they provide the first evidence that aspects of the behavioral serotonin syndrome are mediated by forebrain hypothalamic receptors.Measurements of hormone release and thermoregulatory responses to acute challenge with serotonergic releasing agents or clinically approved partial 5-HT1A receptor agonists have been used to assess the sensitivity of serotonergic function in patients suffering from various psychological disorders such as depression, obsessive compulsive disorder, or post-traumatic stress (Lesch et al., 1990a(Lesch et al., , 1991Flory et al., 1998;Rinne et al., 2000;Shapira et al., 2000). Administration of serotonin-releasing agents, as well as 5-HT1A receptor agonists, produces a distinct profile of stress hormone release characterized, in part, by increased plasma levels of adrenocorticotropin hormone (ACTH), prolactin, and cortisol in human subjects Sherman, 1984, 1985; Lesch et al., 1990a,b). Depressed patients demonstrate a blunted release of ACTH and cortisol in response to acute administration of partial 5-HT1A receptor agonists (Lesch et al., 1990a;Shapira et al., 2000). Positron emission tomography studies demonstrate reduced 5-HT1A receptor binding in several brain regions in both depressed patients as well as those diagnosed with panic disorder (Sargent et al., 2000;Neumeister et al., 2004). The...

show abstract

Inhibition of 8-OH-DPAT-induced elevation of plasma corticotrophin by the 5-HT1A receptor antagonist WAY100635

Cited by 35 publications

References 10 publications

Desensitization of 5-HT_1AReceptors by 5-HT_2AReceptors in Neuroendocrine Neurons in Vivo

Desensitization of 5-HT_1AReceptors by 5-HT_2AReceptors in Neuroendocrine Neurons in Vivo

A role for serotonin in the antidepressant activity of NG-Nitro-L-arginine, in the rat forced swimming test

5-Hydroxytryptamine 1A Receptors in the Paraventricular Nucleus of the Hypothalamus Mediate Oxytocin and Adrenocorticotropin Hormone Release and Some Behavioral Components of the Serotonin Syndrome

Contact Info

Product

Resources

About

Inhibition of 8-OH-DPAT-induced elevation of plasma corticotrophin by the 5-HT1A receptor antagonist WAY100635

Cited by 35 publications

References 10 publications

Desensitization of 5-HT1AReceptors by 5-HT2AReceptors in Neuroendocrine Neurons in Vivo

Desensitization of 5-HT1AReceptors by 5-HT2AReceptors in Neuroendocrine Neurons in Vivo

A role for serotonin in the antidepressant activity of NG-Nitro-L-arginine, in the rat forced swimming test

5-Hydroxytryptamine 1A Receptors in the Paraventricular Nucleus of the Hypothalamus Mediate Oxytocin and Adrenocorticotropin Hormone Release and Some Behavioral Components of the Serotonin Syndrome

Contact Info

Product

Resources

About

Desensitization of 5-HT_1AReceptors by 5-HT_2AReceptors in Neuroendocrine Neurons in Vivo

Desensitization of 5-HT_1AReceptors by 5-HT_2AReceptors in Neuroendocrine Neurons in Vivo